Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust

 
back
1 Gastro-intestinal system
01-05-03 Cytokine inhibitors

Adalimumab
Formulary
Link  NICE TA 187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
 

Red View adult BNF  View SPC online  HCD
Golimumab
Formulary
Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
 

Red View adult BNF  View SPC online  HCD
Infliximab See 10.01.03 for preparations
Formulary
Link  NICE TA 163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA 187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
 

Red View adult BNF  View SPC online  HCD
Biosimilar Infliximab Inflectra®
Formulary

Vial (powder for reconstitution): 100mg


Red View adult BNF  View SPC online  HCD
Ustekinumab Stelara
Formulary

Concentrate for solution for infusion: 130mg

Link  NICE TA 456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Link  NICE TA 633: Ustekinumab for treating moderately to severely active ulcerative colitis
 

Red View adult BNF  View SPC online